PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase II open-label single-arm prospective multicentric clinical trial of PF-05212384 (PKI-587) delivered by intravenous route. A 2-stage Fleming design will be employed.
Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome|Acute Myeloid Leukemia, in Relapse|de Novo Acute Myeloid Leukemia at Diagnostic
DRUG: PF-05212384
To evaluate the efficacy of PF-05212384, The overall response rate will be assessed according to the International Working Group (IWG) AML and MDS criteria (by B.D. Cheson)., 4 months after treatment
Tolerance and toxicity during treatment, Issued the Common Terminology Criteria for Adverse Events (CTCAE) version 4 National Cancer Institute (NCI), 4 months|Treatment compliance, Treatment compliance will be assessed by the ratio between the number of cycles administered on the expected number of cycles, and on time between treatment cycles, 4 months|Progressive Free Survival (PFS), Progressive Free Survival at one year from the date of inclusion to the date of progression of the disease or death, one year|Overall survival, Overall Survival from the date of inclusion to the date of death, 48 months|Evaluation of Quality of life, Quality of life (QLQ-C30) questionnaire according to European Organisation for Research and Treatment of Cancer (EORTC), 4 months
The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.

Blood tests (hemogram) are assessed weekly before each injection of PF-05212384 (PKI-587). Bone marrow aspiration (myelogram) is performed to evaluate the response before starting treatment and before the start of cycle 3 (after two cycles) and at the end of the study (after four cycles). Good responders who continue treatment after four cycles will be evaluated by bone marrow aspiration (myelogram) every two cycles and after the end of treatment